Description: Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Home Page: www.intensitytherapeutics.com
1 Enterprise Drive
Shelton,
CT
06484-4779
United States
Phone:
203-221-7381
Officers
| Name | Title |
|---|---|
| Mr. Lewis H. Bender M.A., M.B.A., M.S. | Founder, President, CEO & Chairman of the Board |
| Mr. Joseph Talamo CPA, M.B.A. | Chief Financial Officer |
| Mr. John Wesolowski CPA, M.B.A. | Principal Accounting Officer & Controller |
| Mr. James M. Ahlers | Executive Vice President of Corporate Finance |
| Mr. Brian Schwartz M.D. | Executive Vice President of Clinical Development |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 11.2218 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-06-30 |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |